JP2005516996A - 脂質可動化、グリコーゲン可動化、またはその両方をヒトにおいて促進するための組成物および方法 - Google Patents

脂質可動化、グリコーゲン可動化、またはその両方をヒトにおいて促進するための組成物および方法 Download PDF

Info

Publication number
JP2005516996A
JP2005516996A JP2003565503A JP2003565503A JP2005516996A JP 2005516996 A JP2005516996 A JP 2005516996A JP 2003565503 A JP2003565503 A JP 2003565503A JP 2003565503 A JP2003565503 A JP 2003565503A JP 2005516996 A JP2005516996 A JP 2005516996A
Authority
JP
Japan
Prior art keywords
residue
xaa
amino acid
human
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003565503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516996A5 (https=
Inventor
シャクター，バーニス・ズィー
シャクター，リー・ピー
Original Assignee
ビーエルエム・グループ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビーエルエム・グループ filed Critical ビーエルエム・グループ
Publication of JP2005516996A publication Critical patent/JP2005516996A/ja
Publication of JP2005516996A5 publication Critical patent/JP2005516996A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
JP2003565503A 2002-02-07 2003-02-07 脂質可動化、グリコーゲン可動化、またはその両方をヒトにおいて促進するための組成物および方法 Withdrawn JP2005516996A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/072,419 US6852693B2 (en) 2002-02-07 2002-02-07 Compositions and methods for promoting lipid mobilization in humans
PCT/US2003/003800 WO2003066080A1 (en) 2002-02-07 2003-02-07 Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans

Publications (2)

Publication Number Publication Date
JP2005516996A true JP2005516996A (ja) 2005-06-09
JP2005516996A5 JP2005516996A5 (https=) 2006-03-30

Family

ID=27732307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565503A Withdrawn JP2005516996A (ja) 2002-02-07 2003-02-07 脂質可動化、グリコーゲン可動化、またはその両方をヒトにおいて促進するための組成物および方法

Country Status (7)

Country Link
US (3) US6852693B2 (https=)
EP (1) EP1480668A1 (https=)
JP (1) JP2005516996A (https=)
AU (1) AU2003210923A1 (https=)
CA (1) CA2474203A1 (https=)
WO (1) WO2003066080A1 (https=)
ZA (1) ZA200406715B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852693B2 (en) * 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans
WO2005067912A1 (en) * 2004-01-02 2005-07-28 Washington University In St. Louis Method of intentionally, noninvasively, therapeutically modulating fat in a living mammal
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2010051347A1 (en) * 2008-10-31 2010-05-06 David Sheikh-Hamad A method for cardioprotection
AU2010210600B2 (en) * 2009-02-06 2016-07-14 C3 Jian, Inc. Calcium-binding agents induce hair growth and/or nail growth
EP3119416B1 (en) 2015-03-26 2017-12-20 Mutlu, Oguz Therapeutic use of adipokinetic hormone/red pigment-concentrating hormone (akh/rpch) family of peptides
TR201712479A2 (tr) 2017-08-22 2019-05-21 Oguz Mutlu Adi̇poki̇neti̇k hormon/kirmizi pi̇gment-konsantre edi̇ci̇ hormon (akh/rpch) pepti̇t ai̇lesi̇ni̇n yeni̇ terapöti̇k kullanimlari
KR102380290B1 (ko) * 2020-06-15 2022-03-29 대한민국 아메리카왕거저리 유충 추출물을 포함하는 비만 예방 또는 치료용 조성물
KR102380291B1 (ko) * 2020-06-15 2022-03-29 대한민국 풀무치 추출물을 포함하는 비만 예방 또는 치료용 조성물
GB202215797D0 (en) 2022-10-25 2022-12-07 Solasta Bio Ltd Insect neuropeptide analogues
US12281143B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 1
US12302908B2 (en) 2023-10-23 2025-05-20 Solasta Bio Limited Insect neuropeptides 4
US12356995B2 (en) 2023-10-23 2025-07-15 Solasta Bio Limited Insect neuropeptides 9
US12245596B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 8
US12245588B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 2
US12279621B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 3
PL4545546T3 (pl) * 2023-10-23 2026-03-09 Solasta Bio Limited Owadzie neuropeptydy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260601A (en) 1979-10-23 1981-04-07 Nyegaard & Co. A/S Chemical compounds
US4328134A (en) 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
US4489059A (en) 1982-05-07 1984-12-18 Rossini Aldo A Anorexigenic composition and method
US4464356A (en) 1982-05-07 1984-08-07 Mordes John P Anorexigenic composition and method
US4891219A (en) 1986-03-14 1990-01-02 Aphton Corporation Method for immunization against and treatment of infection by ectoparasites and endoparasites
GB8806471D0 (en) 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
FR2710340B1 (fr) 1993-09-22 1995-12-15 D Hinterland Lucien Dussourd Dérivés peptidiques de l'alpha-MSH et leur application .
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US6852693B2 (en) * 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans

Also Published As

Publication number Publication date
US20040224898A1 (en) 2004-11-11
CA2474203A1 (en) 2003-08-14
AU2003210923A1 (en) 2003-09-02
US20030162717A1 (en) 2003-08-28
US7314865B2 (en) 2008-01-01
WO2003066080A1 (en) 2003-08-14
US6852693B2 (en) 2005-02-08
EP1480668A1 (en) 2004-12-01
US8067363B2 (en) 2011-11-29
ZA200406715B (en) 2006-06-28
US20090036383A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
US8067363B2 (en) Compositions and methods for promoting lipid mobilization in humans
JP5792925B2 (ja) 過剰体重を防止または治療するためのオキシンソモジュリン
US20170027897A1 (en) mTORC1 MODULATION BY AMINO ACIDS AND USES THEREOF
Érces et al. N-methyl-D-aspartate receptor antagonist therapy suppresses colon motility and inflammatory activation six days after the onset of experimental colitis in rats
JP2022514125A (ja) Ｆａｓ信号伝達抑制用ペプチドを含む肥満、脂肪肝又は脂肪肝炎の予防又は治療用薬学的組成物
US20220175713A1 (en) Depside trimeric compounds for skeletal muscle modulation
US20220184025A1 (en) Novel depside dimeric compounds for skeletal muscle modulation, methods and uses thereof
KR102118953B1 (ko) 골손실의 완화, 치료 또는 예방용 약학조성물 및 건강기능식품
EP3509619B1 (en) Peptides and peptide conjugates for treating mental disorders
US9155778B2 (en) Tripeptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SgIt1
JP4422103B2 (ja) 疲労を回復又は軽減するための組成物、および当該組成物を備える医用デバイス
JP7356710B2 (ja) ペリオスチン及びｐｋｍ２の分泌促進剤
US10105414B2 (en) Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
JP2022183336A (ja) ペプチド、組成物及び気分障害を治療、予防、又は改善する方法
KR102118116B1 (ko) Foxp3 또는 이를 코딩하는 유전자를 포함하는 나노입자 및 이의 용도
KR101499286B1 (ko) 시난디온 ａ를 포함하는 항염증용 조성물
KR20250023259A (ko) 근육 감소 억제 효과를 갖는 갈색거저리 유충 단백 가수분해 펩타이드 조성물
KR101796835B1 (ko) Cacul1 단백질을 포함하는 전립선암의 예방 또는 치료용 약학 조성물
Primaverile Societ& Italiana di Fisiologia XV Riunione Primaverile (Spring Meeting)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071115